Finance
Genasense maker reports first quarter revenues of $1.7 million
Published in Medical Letter on the CDC and FDA, May 30th, 2004
The company reported revenues of $1.7 million for the quarter, a net loss of $12.5 million or $0.16 per share, and cash, cash equivalents, and marketable securities totaling $67.5 million.
During the quarter, the U.S. Food and Drug Administration (FDA) accepted the Genasense (oblimersen sodium) Injection new drug application for use in combination with dacarbazine for the treatment of patients with advanced melanoma who have not received prior chemotherapy.
The FDA granted priority review status to the application, which targets an...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Anthrax
Anthrax lethal toxin neutralization assay validated - DNA Microarray
Correction for dye-bias in microarray gene expression studies reported - Hormone Replacement Therapy
Postmenopausal estrogen guidelines for treating hot flashes released - Lead Poisoning
Lead-contaminated moonshine constitutes significant health hazard - Mycobacterium
M. tuberculosis strain with resistance to isoniazid identified - AIDS/HIV Therapy
Lymphocytes in transgenic mice are resistant to viral infection - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
